<DOC>
	<DOCNO>NCT02856425</DOCNO>
	<brief_summary>Both anti-angiogenesis anti PD1 immunotherapy show beneficial efficacy solid tumor particular NSCLC . Therefore interest investigate whether combination two approach tolerable . Moreover , comprehensive pre-clinical clinical rationale sustain hypothesis anti-VEGF could synergize immunotherapy benefit patient .</brief_summary>
	<brief_title>Trial Of Pembrolizumab And Nintedanib</brief_title>
	<detailed_description />
	<mesh_term>Nintedanib</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>1 . Age ≥ 18 2 . Cytologically histologically confirm diagnosis advance solid tumor initial cohort ( tumor type ) . And Expansion cohort : 2.1 . Patients locally advance , metastatic locally recurrent nonsmall cell lung cancer ( NSCLC ) adenocarcinoma tumor histology 2.2 Patients locally advanced , metastatic locally recurrent nonsmall cell lung cancer ( NSCLC ) squamous cell tumor histology 2.3 . Patients advanced Urothelial cancer 2.4 . Patients advance Renal Cell cancer ( RCC ) 2.5 . Patients refractory CRC failure standard chemotherapy biological agent 2.6 . Patients advanced Ovarian cancer ( OC ) 2.7 . Patients advance Hepatocellular ( HCC ) 2.8 . Patients advanced Mesothelioma ( MPM ) others 3 . ECOG performance status score 0 1 4 . Adequate organ function define follow criterion : Proteinuria ≤ Grade 2 NCI CTCAE v4.03 Serum creatinine ≤1.5 x ULN calculate creatinine clearance ≥ 40 mL/min Total bilirubin ≤1.5 x ULN AST ALT ≤2.5 x upper limit normal ( ULN ) ; liver metastasis AST ALT ≤5.0 x ULN Coagulation parameter : International normalized ratio ( INR ) &lt; 3 , prothrombin time ( PT ) partial thromboplastin time ( PTT ) &lt; 50 % deviation ULN Absolute Neutrophils count ( ANC ) ≥1 500 cells/mm3 Platelets ≥100 000 cells/mm3 Hemoglobin ≥ 9.0 g/dL Lymphocytes count ≥ 1000/ mm3 CD4+ count ≥ 500/ mm3 assess routine blood phenotyping 5 . Failure least one prior line chemotherapy 6 . At least one measurable lesion accord RECIST v1.1 criterion baseline prerequisite assessment principal judgment criterion . 7 . Women childbearing potential ( WOCBP ) must negative serum urine pregnancy test within 7 day prior initiation treatment . Both sexually active female male ( female partner ) patient must agree use two method effective contraception , one barrier method , abstain sexual activity study least 4 month last study drug administration . 8 . Signed date write informed consent prior admission study 9 . Patient affiliate social security regimen beneficiary 1 . Prior treatment nintedanib 2 . Known hypersensitivity trial drug excipients , peanut soya contrast medium 3 . Prior treatment pembrolizumab anti PD1 antiPDL1 agent 4 . Concurrent steroid medication ( except topical aerosol steroid ) . Any steroid medication stop 7 day prior begin therapy . 5 . History autoimmune/immune mediate inflammatory disease , include limited colitis , pneumonitis , hepatitis , hypophysitis , nephritis , hyperthyroidism , systemic lupus erythematous , rheumatoid arthritis , inflammatory bowel disease , Wegener 's granulomatosis , Sjögren 's syndrome , GuillainBarré syndrome , vasculitis , glomerulonephritis except stable hypothyroidism stable Type 1 diabetes mellitus . 6 . Chemo , hormono , radio ( except brain extremity ) immunotherapy therapy monoclonal antibody small tyrosine kinase inhibitor within past 4 week 5 halflife time ( whatever short ) prior treatment trial drug . 7 . Administration live , attenuated vaccine within 4 week registration 8 . Treatment systemic immunosuppressive medication ( include limited steroid azathioprine , methotrexate , thalidomide , antitumor necrosis factor [ antiTNF ] agent ) within 2 week prior registration 9 . Radiotherapy target lesion ( unless progression radiotherapy document ) 10 . Persistence clinically relevant treatmentrelated toxicity previous chemotherapy , target therapy and/or radiotherapy 11 . Active brain metastasis leptomeningeal disease . Clinically asymptomatic brain metastasis allow ( treatment steroid prior initiation trial allow ) . Patients Diffuse Intrinsic Pontine Gliomas , even asymptomatic , allow . 12 . Radiographic evidence cavitary necrotic tumor tumor local invasion major blood vessel 13 . History clinically significant hemoptysis within past 3 month ( one teaspoon fresh blood per day ) 14 . Treatment investigational drug treatment another clinical trial within past 4 week start therapy concomitantly trial 15 . Therapeutic anticoagulation drug require INR monitoring ( except lowdose heparin and/or heparin flush need maintenance indwell intravenous devise ) antiplatelet therapy ( except lowdose therapy acetylsalicylic acid &lt; 325mg per day ) 16 . Major injury and/or surgery within past 4 week prior start study treatment incomplete wound heal and/or plan surgery ontreatment study period 17 . History clinically significant hemorrhagic thromboembolic event past 6 month 18 . Known inherited predisposition bleed thrombosis 19 . History significant cardiovascular disease ( i.e . uncontrolled hypertension , unstable angina , history infarction within past 12 month prior start study treatment , congestive heart failure &gt; NYHA II , serious cardiac arrhythmia , pericardial effusion ) 20 . Ongoing uncontrolled autoimmune thyroiditis . Ancient thyroiditis currently stable substitutive therapy exclude trial . 21 . Other malignancy within past 5 year basal cell skin cancer carcinoma situ cervix 22 . Active serious infection particular require systemic antibiotic antimicrobial therapy 23 . Active chronic hepatitis C and/or B infection . Patients past/resolved HBV infection ( define presence antihepatitis B core antibody , IgG antiHBs + ) eligible . HBV DNA obtain patient prior Day 1 . Patients positive HCV antibody eligible PCR negative HCV RNA . 24 . Known human immunodeficiency virus ( HIV ) positive ; 25 . Gastrointestinal disorder abnormality would interfere absorption study drug 26 . Serious illness concomitant nononcological disease neurologic , psychiatric , infectious disease active ulcer ( gastrointestinal tract , skin ) laboratory abnormality may increase risk associate study participation study drug administration judgment investigator would make patient inappropriate entry study . 27 . Pregnancy breast feeding , 28 . Psychological , familial , sociological geographical factor potentially hamper compliance study protocol followup schedule 29 . Active alcohol drug abuse 30 . Significant weight loss ( &gt; 10 % BW ) within past 6 month prior inclusion trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>